CA2624618C - Av.beta.6 peptide ligands and their uses - Google Patents

Av.beta.6 peptide ligands and their uses Download PDF

Info

Publication number
CA2624618C
CA2624618C CA2624618A CA2624618A CA2624618C CA 2624618 C CA2624618 C CA 2624618C CA 2624618 A CA2624618 A CA 2624618A CA 2624618 A CA2624618 A CA 2624618A CA 2624618 C CA2624618 C CA 2624618C
Authority
CA
Canada
Prior art keywords
peptide
peptides
binding
avp6
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2624618A
Other languages
English (en)
French (fr)
Other versions
CA2624618A1 (en
Inventor
Mark J. Howard
Danielle Dicara
John F. Marshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to CA2854550A priority Critical patent/CA2854550C/en
Publication of CA2624618A1 publication Critical patent/CA2624618A1/en
Application granted granted Critical
Publication of CA2624618C publication Critical patent/CA2624618C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2624618A 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses Active CA2624618C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2854550A CA2854550C (en) 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0520068A GB0520068D0 (en) 2005-10-03 2005-10-03 av peptide ligand
GB0520068.8 2005-10-03
PCT/GB2006/003673 WO2007039728A2 (en) 2005-10-03 2006-10-03 AVß6 PEPTIDE LIGANDS AND THEIR USES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2854550A Division CA2854550C (en) 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses

Publications (2)

Publication Number Publication Date
CA2624618A1 CA2624618A1 (en) 2007-04-12
CA2624618C true CA2624618C (en) 2016-03-29

Family

ID=35395162

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2624618A Active CA2624618C (en) 2005-10-03 2006-10-03 Av.beta.6 peptide ligands and their uses
CA2854550A Active CA2854550C (en) 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2854550A Active CA2854550C (en) 2005-10-03 2006-10-03 .alpha.v.beta.6 peptide ligands and their uses

Country Status (7)

Country Link
US (3) US8383593B2 (https=)
EP (1) EP1957522B1 (https=)
JP (1) JP5449774B2 (https=)
CA (2) CA2624618C (https=)
ES (1) ES2638439T3 (https=)
GB (1) GB0520068D0 (https=)
WO (1) WO2007039728A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
GB0718843D0 (en) 2007-09-26 2007-11-07 Cancer Rec Tech Ltd Materials and methods relating to modifying the binding of antibodies
MX342270B (es) * 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
WO2013025261A2 (en) * 2011-04-06 2013-02-21 Georgia Tech Research Corporation Fluorogenic peptide probes and assays
WO2013078250A2 (en) * 2011-11-22 2013-05-30 The Board Of Trustees Of The Leland Stanford Junior University Cystine knot peptides that bind alpha-v-beta-6 integrin
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
US9282120B2 (en) * 2013-02-01 2016-03-08 Vidder, Inc. Securing communication over a network using client integrity verification
GB201311031D0 (en) * 2013-06-20 2013-08-07 Queen Mary & Westfield College Method
JP6789823B2 (ja) * 2014-04-15 2020-11-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 両末端ｐｅｇ化インテグリン結合性ペプチドおよびその使用方法
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3468984A4 (en) * 2016-06-13 2020-03-11 The Regents of the University of California ALPHA (V) BETA (6) BINDING PEPTIDES AND METHODS OF USE THEREOF
BR112018076184A2 (pt) * 2016-06-16 2019-03-26 The University Of Liverpool composição sólida, composição farmacêutica ou veterinária na forma injetável, formulação intramuscularmente injetável, formulação subcutaneamente injetável, dispersão aquosa, dispersão oleosa, processos para preparar uma composição sólida, uma dispersão aquosa e uma dispersão oleosa, métodos para tratar e/ou prevenir uma infecção parasítica ou fúngica e para prevenir malária, e, kit para preparação de uma formulação líquida estéril de nanopartículas de atovaquona para injeção.
ES3023938T3 (en) 2016-09-29 2025-06-03 Univ California Neutralizing antibodies to the alpha v beta 8 integrin complex for immunotherapy
SI3535397T1 (sl) * 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
JP7445594B2 (ja) 2017-11-01 2024-03-07 アローヘッド ファーマシューティカルズ インコーポレイテッド インテグリンリガンドおよびその使用
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
EP3846858A4 (en) * 2018-09-07 2022-10-19 The Regents of the University of California Alpha(v)beta(6) integrin-binding peptides and methods of use thereof
AU2020370362A1 (en) * 2019-10-25 2022-06-02 Children's Medical Center Corporation Computational design of alpha(v) beta (6) integrin binding proteins
WO2021094608A1 (en) * 2019-11-15 2021-05-20 Ospedale San Raffaele S.R.L. Chromogranin a-derived peptides and uses thereof
US12486502B2 (en) 2021-04-08 2025-12-02 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use
WO2022221144A1 (en) * 2021-04-12 2022-10-20 University Of Washington Engineered peptides for αvβ6 integrin binding and related methods of use and synthesis
CN115010949B (zh) * 2022-07-12 2024-02-13 华熙生物科技股份有限公司 促渗物、护肤品组合物以及化妆品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301928D0 (en) 1983-01-24 1983-02-23 Nicholson B H Process for producing polypeptides
JPS60103596A (ja) * 1983-11-11 1985-06-07 Toshiba Corp サンプル・ホ−ルド回路
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
EP1140989A1 (de) 1998-12-19 2001-10-10 MERCK PATENT GmbH Inhibitoren des integrins alpha(v) beta(6)
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
JP2003534558A (ja) * 2000-05-26 2003-11-18 グラクソ グループ リミテッド ＬＡＰ（潜在型結合ペプチド）とインテグリンαｖβ３との間の相互作用のモジュレーターを同定する方法及びその医学的使用
US20030031648A1 (en) * 2000-11-28 2003-02-13 Virogene Ltd. Vectors for expressing heterologous peptides at the amino-terminus of potyvirus coat protein, methods for use thereof, plants infected with same and methods of vaccination using same
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand

Also Published As

Publication number Publication date
EP1957522A2 (en) 2008-08-20
ES2638439T3 (es) 2017-10-20
WO2007039728A3 (en) 2007-09-20
US20150125392A1 (en) 2015-05-07
US20090123370A1 (en) 2009-05-14
CA2624618A1 (en) 2007-04-12
US20130149248A1 (en) 2013-06-13
WO2007039728A2 (en) 2007-04-12
CA2854550C (en) 2020-04-14
JP2009509562A (ja) 2009-03-12
CA2854550A1 (en) 2007-04-12
GB0520068D0 (en) 2005-11-09
EP1957522B1 (en) 2017-07-12
US9650416B2 (en) 2017-05-16
US8383593B2 (en) 2013-02-26
JP5449774B2 (ja) 2014-03-19
US8927501B2 (en) 2015-01-06

Similar Documents

Publication Publication Date Title
US9650416B2 (en) αvβ6 peptide ligands and their uses
JP2019218358A (ja) 構造化ポリペプチドの特異性のモジュレーション
Dewan et al. Crystal structure of. kappa.-Bungarotoxin at 2.3-. ANG. resolution
JP2015534568A (ja) Ｉｒｆ５に結合する細胞透過性ペプチド
US9409961B2 (en) Cell penetrating peptides to target EIF4E
JP2022518210A (ja) インテグリンαｖβ３に特異的な二環式ペプチドリガンド
EP3596102B1 (en) Structure-based peptide inhibitors that target the tau vqiink fibrillization segment
CA2632451A1 (en) Cell penetrating peptides for intracellular delivery of molecules
EP3541409B1 (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
CN110092817A (zh) 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
US11174298B2 (en) Preparation and use of ginsentides and ginsentide-like peptides
EP2721060A2 (en) Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
US20220267376A1 (en) P53 activator peptidomimetic macrocycles
CN108640974B (zh) 一种靶向作用Syntenin蛋白PDZ结构域的多肽及其二聚体
JP7726464B2 (ja) Ｂｉｇ３－ｐｈｂ２相互作用阻害ｐｈｂ２由来ペプチドを含む乳がん治療薬
CN114450399A (zh) 用于治疗癌症的乳酸脱氢酶抑制剂多肽
CA3041727C (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
EP3906935A1 (en) Peptides for preventing or treating viral infections
WO2026085280A1 (en) Cell-penetrating peptides with enhanced solubility
HK40015109A (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
HK40015109B (en) Engineered tgf-beta monomers and their use for inhibiting tgf-beta signaling
HIV YOUNG INVESTIGATORS ABSTRACTS
WO2011132938A2 (ko) Gpcr에 특이적으로 결합하는 gpcr-bpb
Herrera Evaluation of NMR structural studies on a family of membrane active channel forming peptides

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240923

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240923

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240923

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250926